Two decades ago, before medical marijuana was legal in my home state of Rhode Island, access to high-quality cannabis was inconsistent at best. Occasionally, a college classmate would return from the West Coast with carefully grown flower — aromatic and clearly cultivated with intention. But most of what circulated locally was ultra low-grade imported cannabis: compressed, seed-filled, harsh. Even then, long before legalization or retail frameworks existed, one thing was obvious — cannabis quality fundamentally shaped the experience. As a regular user, when the product wasn’t right, I often chose not to consume at all.
My early understanding became more than philosophical in 2006, when I developed severe insomnia. Night after night, I slept no more than an hour. I experimented with conventional solutions — including pharmaceuticals, meditation and alternative medicine — with no meaningful improvement. Several physicians, reflecting the prevailing medical bias of the time, suggested cannabis might be contributing to the problem rather than alleviating it. My radical therapist, however, took a different view.
Instead of dismissing cannabis outright, we treated it as a variable worth examining. I tracked dosage, timing and method of consumption, along with sleep duration and perceived quality of rest. Patterns emerged quickly. Heavy consumption immediately before bed was counterproductive, often leaving me overstimulated. But consistent, measured use beginning earlier in the evening — maintained deliberately — produced longer, deeper sleep.
One factor, however, remained unpredictable: product quality. Even as my access improved marginally, inconsistency persisted. Potency and effect varied widely while terpene profiles were unreliable to nonexistent. In some cases, the effects felt less related to cannabinoid content and more to questionable inputs. Because bad medicine was better than no medicine, I often consumed low-quality product, even when observing less than optimal outcomes from such product.
As higher-quality flower gradually became more available and low-grade imports disappeared from my local market, consistency emerged. I was able to calibrate my consumption more precisely, of course with variability pertaining to my own individual response to new strains. Even when I was relegated to a strain that didn’t affect my body precisely as needed, my ability to sleep was still far better than when I medicated with low-quality cannabis. Within six months, my sleep normalized to seven or eight hours per night. The cumulative impact of chronic sleep deprivation taught me a simple truth: cannabis works best when overall quality is paramount.
For years afterward, my relationship with the plant remained stable. I consumed for both wellness and recreation, always prioritizing clean flavor, smooth combustion and predictable effects. Quality was a baseline expectation of any cannabis purchase. Then, in 2019, after a prolonged period of unexplained health issues, I was diagnosed with celiac disease. Eliminating gluten resolved the primary symptoms but introduced a new complication: the damage done to my digestive tract, likely over years, had completely removed my body’s hunger signals. My complete loss of appetite lead to a 40-pound weight loss in two months.
Once again, I turned to cannabis as a functional tool.
By that time, adult-use retail sales had launched in Massachusetts. Legal access had finally arrived and, with it, the promise of consistency. What I encountered instead was a familiar gap I have heard about all over the country. After sampling a wide cross-section of the market, a clear pattern emerged: much of the flower was over-dried, improperly cured, terpene-deficient or aged well beyond peak usability. Regulatory compliance was high while experiential quality was not. The legal framework had matured faster than the product itself.
This disconnect was understandable. Regulatory constraints, capital pressure, limited operational experience and compressed timelines all pushed producers to prioritize volume and shelf stability over refinement. The result was a legal market that often failed to deliver what consumers intuitively expected: a better product than what existed before.
Cannabis efficacy is not reducible to THC percentage alone. Terpene preservation, cultivation discipline, harvest timing, post-harvest handling, and storage conditions all materially influence outcomes. The entourage effect is observable in real-world use, and a positive, functional state of intoxication is central to both therapeutic benefit and consumer satisfaction.
Shortly thereafter, I began cultivating medical cannabis alongside my partner, an experienced grower with more than a decade in the field. From the outset, our focus was narrow and deliberate. We treated cultivation as agriculture, not manufacturing. Every decision, from genetics and feeding schedules to drying environments and cure duration, was evaluated through a single lens: does this improve the end experience?
The goal was not simply to deliver cannabinoids efficiently. It was to produce a consistently superior product that respected the plant and the patient alike. Quality, we found, is the result of hundreds of small decisions made consistently over time with an eye toward the best possible product.
Now, in 2026, the East Coast market is beginning to reflect a broader shift. Consumers are more educated, more discerning and increasingly less tolerant of mediocrity. Craft-forward flower is gaining traction, and quality differentiation is starting to matter in a meaningful way as consumer education becomes more widespread. This evolution mirrors patterns long established in other mature consumer categories, including coffee, wine, food and wellness, where early growth prioritizes access, and later stages reward refinement. I have seen ultra high-quality cannabis brands sell thousand-dollar ounces. Ultra-premium, ultra-exclusive cannabis is here.
The next stage of growth will not be defined by expansion alone, but by consistency, trust and repeat engagement.
The direction is clear. The market is moving toward higher standards, whether by consumer demand or competitive pressure. Those who adapt will help define the future of cannabis.
CJ Waterman is a medical marijuana cultivator and co-founder of Pleasant Effects, a premium craft cannabis brand focused on small batch cultivation and quality driven production.